You are here

Innovative treatment methods for autoimmune inflammatory diseases using new biotechnological and polyvector drugs


Work number - M 4 FILED

Presented State Organization «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine».

Authors:
HLADKYKH Fedir Volodymyrovych – PhD in Health Care, Senior Research fellow of the State Organization ''Grigoriev Institute for medical Radiology and Oncology of the NAMS of Ukraine''.

The purpose of the present experimental work is the search of novel solution to a scientific task aimed at improving the effectiveness and safety of drug therapy for autoimmune diseases. This is achieved by studying the complex mechanisms of action of acellular cryopreserved biological agents (mesenchymal stem cell conditioned medium, cryoextract of placenta, and cryoextract of spleen) and 2-phenyl-3-carbethoxy-4-dimethylaminomethyl-5-hydroxybenzofuran hydrochloride ("Vinboron").

For the first time, the effectiveness of acellular cryopreserved biological agents in the experimental therapy of the most common autoimmune systemic (rheumatoid arthritis) and organ-specific autoimmune diseases: central nervous system (multiple sclerosis), thyroid gland (autoimmune thyroiditis), heart (autoimmune myocarditis), liver (autoimmune hepatitis), and kidneys (autoimmune nephritis) has been established. The author has demonstrated the enhancement of the anti-inflammatory action when non-steroidal anti-inflammatory drugs are combined with cryopreserved placenta extract or Vinboron, due to their effect on the cyclooxygenase and lipoxygenase pathways of inflammation.

The results of the work will expand the range of indications for the use of acellular cryopreserved biological agents and the synthetic agent "Vinboron" as drugs to optimize pharmacotherapy for autoimmune diseases. These findings lay the foundation for the introduction of immunomodulators and cytoprotectors produced in Ukraine for immunology, rheumatology, cardiorheumatology, and other fields of practical healthcare into the pharmaceutical market. The research results have been implemented into the medical practice of healthcare institutions, as well as into the educational and scientific processes of higher education institutions and research organizations.

Number of publications: single-author monograph and 3 collective monographs, 32 articles in journals included in the "A" category (including 5 in international publications) and 32 articles in journals included in the "B" category, 13 abstracts. The total number of citations of the author’s publications/h-index according to the databases is as follows: Web of Science 1/1, Scopus 131/8, Google Scholar 711/17. The author has obtained 4 patents for utility models in Ukraine.

Comments